Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

References

• AlvarezRHPresent and future evolution of advanced breast cancer therapyBreast Cancer Res201012Suppl 2S1
   PubMedGoogle Scholar
• LinderholmBGrankvistKWilkingNJohanssonMTavelinBHenrikssonRCorrelation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatmentJ Clin Oncol20001871423143110735889
   PubMed Web of Science ®Google Scholar
• McLeskeySWTobiasCAVezzaPRFilieACKernFGHanfeltJTumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factorAm J Pathol19981536199320069846989
   PubMedGoogle Scholar
• UzzanBNicolasPCucheratMPerretGYMicrovessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysisCancer Res20046492941295515126324
   PubMed Web of Science ®Google Scholar
• WeidnerNFolkmanJPozzaFTumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinomaJ Natl Cancer Inst19928424187518871281237
   PubMedGoogle Scholar
• BonapaceLCoissieuxMMWyckoffJCessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesisNature2014515752513013325337873
   PubMed Web of Science ®Google Scholar
• Sossey-AlaouiKPluskotaEDavuluriGKindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesisFASEB J20142852260227124469992
   PubMedGoogle Scholar
• KongWHeLRichardsEJUpregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancerOncogene201433667968923353819
   PubMed Web of Science ®Google Scholar
• ScottLJBevacizumab: in first-line treatment of metastatic breast cancerDrugs200767121793179917683175
   PubMedGoogle Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: European Medicines Agency completes its review of Avastin used in breast cancer [Press release 16/12/2010]2010
   Google Scholar
• MilesDWChanADirixLYPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol201028203239324720498403
   PubMed Web of Science ®Google Scholar
• RobertNJDierasVGlaspyJRIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancerJ Clin Oncol201129101252126021383283
   PubMed Web of Science ®Google Scholar
• MoherDCookDJEastwoodSImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analysesLancet199935491931896190010584742
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
   PubMed Web of Science ®Google Scholar
• LuckHJLubbeKReinischMPhase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancerBreast Cancer Res Treat2015149114114925519041
   PubMed Web of Science ®Google Scholar
• MilesDCameronDBondarenkoIBevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationEur J Cancer20177014615527817944
   PubMed Web of Science ®Google Scholar
• RochlitzCBiglerMvon MoosRSAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer – a multicenter, randomized phase III trialBMC Cancer20161678027724870
   PubMedGoogle Scholar
• WeltAMarschnerNLerchenmuellerCCapecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trialBreast Cancer Res Treat201615619710726927446
   PubMed Web of Science ®Google Scholar
• ZielinskiCLangIInbarMBevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trialLancet Oncol201617191230123927501767
   PubMedGoogle Scholar
• FangYQuXChengBThe efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trialsTumour Biol20153631933194125387808
   PubMedGoogle Scholar
• MilesDWDierasVCortesJDuenneAAYiJO’ShaughnessyJFirst-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patientsAnn Oncol201324112773278023894038
   PubMed Web of Science ®Google Scholar
• RobertNJOverall survival in metastatic breast cancer: always our quest but not necessarily a primary endpointBreast Cancer Res Treat2010122191020495865
   PubMedGoogle Scholar
• SharmaSPAvastin saga reveals debate over clinical trial endpointsJ Natl Cancer Inst20121041180080122673590
   PubMedGoogle Scholar
• RaphaelJVermaSOverall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcomeBreast Cancer Res Treat2015150347347825783185
   PubMedGoogle Scholar
• MilesDWde HaasSLDirixLYBiomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerBr J Cancer201310851052106023422754
   PubMed Web of Science ®Google Scholar
• BaisCRabeCWildNComprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications)J Clin Oncol201432suppl 153040
   Google Scholar
• European Medicines Agency: Assessment Report For Avastin (bevacizumab)2011
   Google Scholar
• NCC NetworkNational Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Breast cancer (Version 2. 2017)2017
   Google Scholar
• DelalogeSPérolDBrainEOverall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: results of a multicenter national observational study. 2016 ASCO Annual Meeting. McCormick Place, Chicago, IllinoisJ Clin Oncol201634Suppl abstr 1013
   Google Scholar
• ValeroVForbesJPegramMDMulticenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensJ Clin Oncol20112914915621115860
   PubMed Web of Science ®Google Scholar